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Abstract (249 words) 
Formoterol is a long-acting beta2-adrenoceptor agonist (LABA) used for treatment of asthma 
and exercise-induced bronchoconstriction. Formoterol is usually administered as a racemic 
(rac-) mixture of (R,R)- and (S,S)-enantiomers. While formoterol is restricted by the World 
Anti-Doping Agency (WADA), inhalation of formoterol is permitted to a predetermined dose 
(54 µg/24 hours) and a urine threshold of 40 ng/mL. However, chiral switch enantiopure 
(R,R)-formoterol is available, effectively doubling the therapeutic advantage for the same 
threshold. The aim of this study was to investigate whether formoterol exhibits 
enantioselective urinary pharmacokinetics following inhalation. Six healthy volunteers were 
administered a 12 μg inhaled dose of rac-formoterol. Urine was collected over 24-hours and 
analysed by enantioselective UPLC-MS/MS assay. Total (free drug plus conjugated 
metabolite) median(min-max) rac-formoterol urine levels following inhalation were 
1.96(1.05-13.4) ng/mL, 1.67(0.16-9.67) ng/mL, 0.45(0.16-1.51) ng/mL, 0.61(0.33-0.78) 
ng/mL, and 0.17(0.08-1.06) ng/mL at 2, 4, 8, 12 and 24 hours, respectively, well below the 
2019 urine threshold. The proportion of conjugation differed between enantiomers with 
glucuronide conjugation much greater for (R,R)-formoterol (around 30-60% of total) 
compared to (S,S)-formoterol (0-30%). There was clear evidence of inter-individual 
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enantioselectivity observed in the ratios of (R,R):(S,S)-formoterol, where (S,S)- was 
predominant in free formoterol, and (R,R)- predominant in the conjugated metabolite.  In 
conclusion, rac-formoterol delivered by inhalation exhibits enantioselective elimination in 
urine following single dose administration. Enantioselective assays should be employed in 
doping control to screen for banned beta2-agonist chiral switch products such as (R,R)-
formoterol, and total hydrolysed rac-formoterol is warranted to account for inter-individual 
differences in enantioselective glucuronidation. 
  
Introduction 
Formoterol (USAN, INN, BAN) is a long-acting beta2-adrenoceptor agonist (LABA) widely 
used for the treatment of airways diseases, particularly asthma and exercised-induced 
bronchoconstriction (EIB). Formoterol is a chiral compound consisting of (R,R)- and (S,S)-
enantiomers, most commonly administered as 50:50 racemic (rac-) mixture with clinical use 
almost always preferred via inhalation. The (R,R)-formoterol enantiomer elicits the 
pharmacological bronchodilator response, while (S,S)-formoterol is considered 
pharmacologically inert (around 1000x less potent than the R-enantiomer) [1].  
 
There is considerable debate surrounding beta2-agonists with regard to performance 
enhancing effects, with the need for balancing treatment of asthma and EIB while minimising 
the potential for doping [2]. Use of formoterol is restricted by the World Anti-Doping 
Agency (WADA) when taken orally or by other routes such as injection, but is permitted to 
be administered via inhalation (dry powder or metered dose inhaler) within a predetermined 
maximum dose of 54 µg over 24 hours. A corresponding urine threshold and decision limit of 
40 and 50 ng/mL, respectively [3], have been introduced to minimise supratherapeutic 
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inhaled or oral dosing for doping purposes. However, these limits are based on the racemic 
drug [3, 4]. Formoterol is now available in some markets as an enantiopure chiral switch 
product consisting of (R,R)-formoterol (arformoterol). Optical isomer chiral switch products 
such as arfomoterol are prohibited by WADA [3], but enantioselective assays are not used for 
doping control, with only total formoterol reported. There is currently no information on the 
proportion of total drug in urine present as the (R,R)-formoterol  enantiomer after an inhaled 
dose. 
 
In terms of mass balance, around half of administered formoterol is recovered in urine as both 
free drug and metabolites [5, 6]. Following inhaled delivery, formoterol recovered from the 
urine is mostly in the form of unchanged free drug (40-60%), as well as an O-demethylated 
metabolite (5-25%) and glucuronide conjugate (25-40%), the proportion of which may vary 
significantly between individuals [7]. Glucuronidation occurs at the phenolic position as well 
as the formation of a benzyl glucuronide [6]. This glucuronidation metabolism is 
enantioselective [8], and is generally susceptible to considerable pharmacogenetic variability 
[9]. Although rac-formoterol has been on the market for over 20 years, there is still little 
information regarding the pharmacokinetics of each enantiomer following inhaled delivery. It 
has been shown for unconjugated formoterol that urinary (S,S)-formoterol levels are 
consistently higher than (R,R)-formoterol indicating enantioselective pharmacokinetics both 
at high inhaled dose (120 µg) [10] and after oral dosing [5]. Unfortunately, there have been 
no reported studies looking at enantioselective pharmacokinetics of both formoterol and 
respective glucuronide metabolites in urine following inhaled dosing to date. This is highly 
relevant for doping control as formoterol is delivered by inhalation for therapeutic use and a 
threshold limit for total formoterol (free and glucuronide conjugate) is used [4]. 
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Supratherapeutic dosing of beta2-agonists via the inhaled route has been shown to elicit 
performance-enhancing effects [11-15] as well as increase fat oxidation [16]. 
 
It is clear from the short acting beta2-agonist (SABA) salbutamol that there are 
enantioselective differences in metabolism between oral and inhaled routes of administration 
that have the potential to be exploited for doping control purposes. Data extracted from 
Schmekel et al [17] in a repeated dose pharmacokinetic study over 24 hours illustrates the 
significant potential of enantioselective chromatography to develop better approaches to 
salbutamol doping control with a mean 0-24 hour urine S:R ratio of 4.9 for oral versus 2.3 for 
inhaled delivery, presumably due to differences in first-pass metabolism in the liver 
following oral administration. This suggests there is potential to discriminate between 
permitted and prohibited routes of administration using enantiomer ratio and this is the focus 
of ongoing work in our laboratories. 
 
The aim of this study was to investigate whether formoterol does exhibit enantioselective 
urinary pharmacokinetics following inhalation and the extent of inter-subject differences, and 
thereby improving our understanding of bioequivalent systemic levels of the active 
enantiopure (R,R)-formoterol. Secondly, if pharmacokinetic enantioselectivity is observed, 
this may lead to an application in sports doping control.  
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Method 
Subjects 
Six subjects (three females) were included in the study, all physically active in recreational 
sport and aged between 21-45 years of age and BMI within a healthy weight range 18.5-24.9. 
Subjects currently taking formoterol or salmeterol were excluded, along with those with 
moderate or severe persistent asthma according to the National Asthma Council Guidelines 
(Australia) or any contraindications to receiving a beta2-agonist. Subjects were instructed 
how to use a dry powder inhaler, before inhaling two 6 μg doses of formoterol as formoterol 
fumarate dihydrate (Symbicort ® Turbuhaler ®; AstraZeneca, NSW, Australia) one minute 
apart under supervision equivalent to a total dose of 12 μg. Subjects were provided with 
sample containers and self-collected urine at baseline, 2, 4, 8, 12 and 24 hours post dose, each 
± 15 minutes, and stored frozen overnight until being returned to the laboratory the next day 
and stored at -30 °C until analysis. Subjects were asked to avoid dehydration but otherwise 
go about normal activities. All subjects gave informed consent and the study was approved 
by the Human Research Ethics Committee (Tasmania Network); H0014003. 
 
Formoterol enantiomer determination in urine 
Enantioselective formoterol analyses were undertaken using an UPLC-MS/MS (ultra 
performance liquid chromatograph-mass spectrometry) assay that was modified from 
previous work with chiral beta2-agonists in our laboratory [18-21]. An enzyme hydrolysis 
method was used to determine total formoterol enantiomers (free drug plus glucuronide) 
based on the previous method reported by Zhang et al [5], with formoterol glucuronide 
concentration determined by subtracting free (unconjugated parent drug) from total 
formoterol (after hydrolysis).  
  
This article is protected by copyright. All rights reserved. 
In brief, calibration samples were prepared consisting of concentrations of 0.1, 0.5, 2.0, 10, 
40 ng/mL unlabeled formoterol in drug free human urine from rac-formoterol fumarate 
dihydrate (Carbosynth, Compton, UK). Internal standard rac-formoterol-D6 (Toronto 
Research Chemicals, Toronto, Canada) was first added to each study urine sample (400 μL) 
or calibration urine sample equivalent to 10 ng/mL in an Eppendorf® centrifuge tube.  
 
Dilute ammonia solution (100 μL) was then added to each sample sufficient to give a final 
pH of 8.5 and vortex mixed, before the addition of 850 μL of HPLC grade ethyl acetate. This 
was vortex mixed for one minute and then centrifuged at 15 000 g for five minutes.  The 
organic supernatant was then transferred to a glass autosampler vial, from which the solvent 
was evaporated under nitrogen at 40°C. Extraction of urine was repeated with a second 850 
μL aliquot of ethyl acetate. Combined residue was reconstituted using 80 μL of methanol and 
vortex mixed prior to analysis via UPLC-MS/MS.  To hydrolyse glucuronides of formoterol 
enantiomers, β-glucuronidase (1000 units from Helix pomatia; Sigma-Aldrich, Sydney 
Australia) in 250 µL of 0.1 M acetate buffer (pH 5) was added to each urine sample (250 µL) 
together with 10 ng of rac-formoterol-D6. These samples were incubated in a temperature 
controlled room at 37°C for 21 hours on a table mixer at 200 rpm. After incubation, dilute 
ammonia solution (100 μL) was added to each sample sufficient to give a final pH of 8.5 and 
vortex mixed, then samples were extracted with 2 mL of ethyl acetate and processed and 
analysed in the same manner as the unhydrolysed samples. A calibration curve was 
constructed from the ratio of analyte (R,R)-formoterol to internal standard (R,R)-formterol-D6 
in each sample, and similarly (S,S)-formoterol to internal standard (S,S)-formterol-D6.  
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The UPLC instrument was a Waters Acquity® H-class UPLC system (Waters Corporation, 
Milford, MA). Chromatography was performed using an Astec® CHIROBIOTIC™ T2 chiral 
column (4.6 × 250 mm × 5 μm particles) (Sigma-Aldrich). The UPLC was coupled to a 
Waters Xevo® triple quadrupole mass spectrometer (Waters Corporation). Analyses were 
undertaken using multiple reaction monitoring (MRM) in positive electrospray ionisation 
mode. The UPLC was operated with a mobile phase consisting of 100% methanol with 0.2% 
acetic acid and 0.025% ammonium hydroxide.  Elution was isocratic for 30 min.  The flow 
rate was 0.8 mL/min and the column was held at room temperature. Injection volume was 50 
μL. Electrospray ionisation was performed with a capillary voltage of 2.76 KV, a cone 
voltage of 30 V and individual collision energies for each MRM transition, as described 
below. The desolvation temperature was 450°C, nebulising gas was nitrogen at 950 L/h and 
cone gas was nitrogen at 50 L/h. MRM transition monitored for formoterol was (m/z) 345 to 
149,  (collision energy 19 V),  and MRM transition monitored for formoterol-D6 was (m/z) 
351 to 155,  (collision energy 19 V). Dwell time per channel was 36 ms. Confirmation of 
enantiomer elution order was undertaken by analysis of (R,R)-formoterol standard (TLC 
Pharmaceutical Standards, Ontario, Canada). Basic assay performance measures (sensitivity, 
precision, accuracy, recovery, and linearity evaluated by r
2
) were all determined as per 
standard laboratory protocols, with method detection limit defined as a signal-to-noise ratio 
of 3 and lower limit of quantification as a signal-to-noise ratio of 10 [22]. The “drop 
perpendicular” method of peak integration was used where a vertical line from the valley of 
the peaks is dropped to the horizontal baseline. 
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Statistical Analysis 
Enantioselectivity in urine was determined using log (S,S):(R,R) ratio with one-sample t-test 
against a hypothetical value of 0 (no enantioselectivity). Results were log transformed to 
account for lack of symmetry with ratios less than 1. Analyses were performed using JMP 
11.2.0  (SAS Institute Inc, NC, USA) and GraphPad Prism 6 for Mac OSX (GraphPad 
Software Inc, CA, USA) with results of p<0.05 considered statistically significant.  
  
Results and Discussion 
Formoterol enantiomers were satisfactorily resolved (Figure 1) (< 15% of peak height, peak 
resolution Rs=1.4) to allow accurate and reproducible quantitation with adequate assay 
sensitivity and performance required for determination of urine levels following inhaled 
dosing (Table 1). Figure 1 demonstrates that the background sample matrix baseline from a 
blank urine was low and flat, as expected from an MRM analysis. Of the four most common 
beta2-agonists (salbutamol, terbutaline, formoterol, salmeterol) in our laboratory, we have 
found that formoterol enantiomers are the most difficult to assay using UPLC-MS/MS 
detection. This is due to both the low doses used in inhaled delivery, and the need to optimise 
signal based on a trade-off between peak resolution and MS sensitivity, due to differences in 
electrospray ionisation suppression from the mobile phase additives required for enantiomer 
separation. Analytical performance is summarised in Table 1.  
 
Rac-formoterol has a urinary threshold of 40 ng/mL with a decision limit of 50 ng/mL 
consisting of parent drug and glucuronide [4]. These limits are based on maximum doses 
permitted by WADA of 54 μg in a 24-hour period [3]. In the present study, we observed total 
(free drug plus conjugated) median(min-max) rac-formoterol urine levels of 1.96(1.05-13.4) 
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ng/mL, 1.67(0.16-9.67) ng/mL, 0.45(0.16-1.51) ng/mL, 0.61(0.33-0.78) ng/mL, and 
0.17(0.08-1.06) ng/mL 2, 4, 8, 12 and 24 hours following inhalation, respectively. Median 
levels of formoterol enantiomers and their respective glucuronide conjugates are shown in 
Table 2. Individual subject enantiomer levels and glucuronide conjugation over time is shown 
in Figure 2, which depicts considerable variation between subjects with respect to overall 
levels and relative proportions of free and conjugated formoterol enantiomers.   
 
The maximum recorded individual urine level (Table 2) of rac-formoterol (free plus 
glucuronide) was 13.4 ng/mL which is in broad agreement with previous work that has been 
undertaken at higher doses [23-25].  Previous reports have demonstrated a maximum 
concentration of 19.6 ng/mL total drug (free plus glucuronide) following a dose of 18 μg over 
8 hours (one third of daily limit) but most routine samples were below 10 ng/mL [25]. 
Similar results were observed by Deventer et al [23], where maximum concentration of free 
drug was 8.5 ng/mL following a 18 μg dose, and by Eibye et al [24] with a maximum 
concentration of 25.6 ng/mL corrected for specific gravity following inhalation of repetitive 
doses up to 72 μg in 6 hours. This has led to criticisms that the current threshold is too low 
and that further validation is required [23]. While our work did not correct for urine specific 
gravity, other single dose pharmacokinetic studies with high dose inhaled salbutamol has 
demonstrated that exercise and dehydration do affect urine concentrations compared to rest, 
resulting in a greater risk of exceeding the WADA decision limit, but correcting for specific 
gravity results in only modest improvements [26]. 
 
Although free formoterol enantiomers have been previously measured following inhalation 
(albeit at high dose; [10]), to our knowledge, this is the first report of total urine formoterol 
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enantiomer levels (free plus glucuronide) following inhaled dosing, and only the second 
study to report total urine formoterol enantiomer levels in urine (the previous report 
following oral dosing) [5]. Enantioselectivity can be clearly seen in Figure 3 and 4. It is 
evident that the proportion of conjugation differs between enantiomers (Figure 3) where the 
extent of glucuronide conjugation is much greater with (R,R)-formoterol (around 30-60% of 
total) compared to (S,S)-formoterol (0-30%). There is also clear evidence of 
enantioselectivity observed in the ratio of (R,R):(S,S)-formoterol, both for free formoterol, 
and formoterol glucuronide (Figure 4), where (S,S)- is predominant in free formoterol, and 
(R,R)- is predominant in the conjugated metabolite. These ratios are consistent with that 
observed up to eight hours after oral dosing by Zhang et al [5] and as reported by Lecaillon et 
al [10] which measured free drug only. We did not observe any reversed enantioselectivity, 
which was observed in the sole female participant in the study by Zhang et al [5].   
 
The pharmacokinetics of each formoterol enantiomer following inhaled delivery are clearly 
different, but from our work here, it is unclear what effect repeated or cumulative dosing has 
on the ratio. From this data alone, it would seem reasonable to propose that the (S,S):(R,R) 
ratio for conjugated formoterol would be higher with cumulative dosing, and may offer 
discriminatory capability between permitted and prohibited dosing that warrants further 
exploration for doping control applications. Furthermore, from our data, we can see that 
given a rac-formoterol urine level in the first four hours after a dose, based on an (S,S):(R,R) 
of 1.6, only 38% of the drug would be present as pharmacologically active (R,R)-formoterol. 
So not only are there criticisms the current urine threshold is too low for rac-formoterol, if an 
athlete uses a bioequivalent dose chiral switch (R,R)-formoterol product, their levels are 
going to be almost one-third lower for the same therapeutic advantage. Presence of (R,R)-
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formoterol only in urine would be indicative of prohibited arformoterol administration but 
further studies are needed to rule out chiral conversion in an individual. 
 
Conclusion 
Rac-formoterol delivered by inhalation exhibits enantioselectivity in urine following single 
dose administration that changes during the elimination phase. Enantioselective 
pharmacokinetics differs between parent drug and metabolite, and may offer the potential of 
improved discriminatory detection capability for doping applications with formoterol. 
Enantioselective assays should be employed in doping control to screen for banned beta2-
agonist chiral switch products such as (R,R)-formoterol. Quantitative analysis using total 
hydrolysed rac-formoterol is warranted to account for inter-individual differences in 
enantioselective glucuronidation. 
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Table 1. Analytical method performance data of formoterol enantiomers  
 
 (R,R)-formoterol (S,S)-formoterol 
Correlation coefficient r
2
 0.9998 0.9997 
Intra-day accuracy (%, n=5) 
0.1 ng/mL 
2.0 ng/mL 
 
 
5.9 
-1.5 
 
-3.4 
-5.3 
Intra-day precision (%RSD, n=5) 
0.1 ng/mL 
2.0 ng/mL 
 
4.1 
5.6 
 
 
5.5 
1.3 
 
Method detection limit (MDL)
¶ 
ng/mL 
Lower limit of quantification (LLoQ)
 ¶ 
ng/mL 
0.007 
0.022 
0.007 
0.023 
Recovery (%) 98 98 
Freeze-thaw robustness (% loss) 
   20 ng/mL 
 
4.1 
 
2.7 
¶
 method detection limit and lower limit of quantification was determined from the signal-to-noise ratio 
(S/N) at the 0.1 ng/mL level with MDL and LLoQ defined as S/N=3 and S/N=10 respectively 
1
.  
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Table 2. Formoterol enantiomers and their respective glucuronides in urine following 
a single inhaled dose of 12 μg. 
 
 
Time 
 
(R,R)-
formoterol 
 
 
 
Median 
(min-max) 
 ng/mL 
 
(S,S)-
formoterol 
 
 
 
Median 
(min-max)  
ng/mL 
 
 
 
(R,R)-
formoterol 
glucuronide* 
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(min-max)  
ng/mL 
 
(S,S)-
formoterol 
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Median 
(min-max) 
ng/mL 
 
rac-total 
 
 
 
 
Median 
(min-max) 
ng/mL 
 
Fraction of total 
present as 
glucuronide* 
 
 
Median 
(min-max)  
% 
 
0 
 
0.00 
 
 
0.00 
 
0.00 
 
0.00 
  
- 
 
2 
 
0.61 
(0.38-0.96) 
 
 
1.01 
(0.50-1.72) 
 
0.35 
(0.11-7.10) 
 
0.11 
(0-3.64) 
 
1.96  
(1.05-13.4) 
 
 
73 (20-90) 
 
4 
 
0.35 
(0.07-1.00) 
 
 
0.60 
(0.09-1.75) 
 
0.56 
(0.01-4.76_ 
 
0.19 
(0.00-2.16) 
 
1.67  
(0.16-9.67) 
 
50 (28-94) 
 
8 
 
0.12 
(0.03-0.38) 
 
 
0.19 
(0.03-0.58) 
 
0.12 
(0.00-0.47) 
 
0.06 
(0.00-0.17) 
 
0.45  
(0.16-1.51) 
 
 
62 (36-99) 
 
 
12 
 
0.14 
(0.07-0.26) 
 
 
0.17 
(0.09-0.38) 
 
0.11 
(0.00-0.16) 
 
0.05 
(0.00-0.12) 
 
0.61  
(0.33-0.78) 
 
55 (49-82) 
 
 
24 
 
0.06 
(0.03-0.27) 
 
0.08 
(0.03-0.32) 
 
0.03 
(0.00-0.48) 
 
0.00 
(0.00-0.16) 
 
 
0.17  
(0.08-1.06) 
 
87 (40-100) 
 
* Free formoterol equivalents 
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Figure 1. Example UPLC-MS/MS chromatogram of formoterol enantiomers in a 
subject’s urine following a 12 μg inhaled dose of rac-formoterol overlaying a blank urine 
sample; (R,R)-formoterol 0.65 ng/mL and (S,S)-formoterol 1.09 ng/mL. 
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Figure 2. Urine levels (mean±SEM) of formoterol enantiomers (A) and formoterol enantiomer glucuronides (B) following a 12 μg inhaled dose of rac-formoterol demonstrating enantioselective pharmacokinetics. 
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Figure 3.  Extent of conjugation (free formoterol as a proportion of total) for each enantiomer. 
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Figure 4. Enantioselectivity of formoterol (free) and formoterol glucuronide (conjugated) in urine following a 12 μg inhaled dose 
of rac-formoterol demonstrating enantioselective pharmacokinetics, p<0.05 . 
 
 
